KDM5D Knockout A2780 Polyclonal Cells are a focused CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KDM5D gene in the A2780 human ovarian cancer line. This heterogeneous pool contains a diverse array of CRISPR-induced genotypes, collectively representing a loss-of-function system that mitigates clonal bias and enables robust phenotypic assessment in a cell background clinically relevant to ovarian adenocarcinoma research.
The A2780 cell line is an adherent epithelial ovarian adenocarcinoma model originally established from an untreated patient with endometrioid ovarian adenocarcinoma. Recognized for its utility in ovarian cancer investigation, A2780 has been instrumental in studies of hormone response, drug resistance mechanisms, and epigenetic regulation. Its characterized genetic landscape and tumorigenic properties make it a suitable platform for probing the functions of chromatin modifiers such as KDM5D.
The KDM5D gene product is a histone lysine demethylase with specificity for di- and trimethylated lysine 4 on histone H3 (H3K4me2/me3). By catalyzing demethylation, it erases activating chromatin marks and functions as a transcriptional repressor. KDM5D integrates into a broader regulatory network; it interacts with the retinoblastoma tumor suppressor RB1, scaffold protein SIN3A, HDAC-containing corepressor complexes, and polycomb repressive complex 2. Upstream, its activity is modulated by the androgen receptor and RB1, while downstream it suppresses transcription of H3K4-methylated target genes. These molecular connections underscore KDM5D??s role in coordinating chromatin remodeling and gene silencing programs.
Within the A2780 ovarian cancer context, ablation of KDM5D is predicted to raise H3K4me2/me3 levels at specific genomic loci, potentially derepressing genes involved in cell proliferation, apoptosis, and metastatic behavior. This perturbation offers a direct means to dissect KDM5D-dependent epigenetic dysregulation that may contribute to ovarian tumorigenesis. The model is particularly relevant given the documented involvement of KDM5D in cancers and male infertility, suggesting that its loss may reveal novel vulnerabilities in ovarian cancer cells.
Researchers can employ this knockout cell population in a variety of experimental workflows, including high-content screening for KDM5D inhibitors, ChIP-qPCR and western blotting assays to monitor histone H3K4 methylation states, RT-qPCR and RNA-seq to evaluate gene expression changes, and cellular functional assays such as proliferation and colony formation studies. The polyclonal nature ensures consistent supply and reproducible results across experiments. For additional product information and technical guidance, please contact Ascent Research.
